|
2012
|
Invention
|
Oral formulations of glycyl-2-methylprolyl-glutamate. Oral formulations of G-2MePE including micr... |
|
|
Invention
|
Treatment of fragile x syndrome using glycyl-l-2-methylprolyl-l-glutamate. This invention provide... |
|
2011
|
Invention
|
Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals. Embodiments of ... |
|
2010
|
Invention
|
Cognitive enhancement and cognitive therapy using glycyl-l-2-methylprolyl-l-glutamic acid. This i... |
|
|
Invention
|
Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy. Embodiments of t... |
|
2007
|
Invention
|
Substituted pyrrolo[1,2-d][1,4]-diazonines and treatment of brain damage. Embodiments of this inv... |
|
|
Invention
|
Analogs of glycyl-prolyl-glutamate. Embodiments of this invention include novel analogs of Glycyl... |
|
2006
|
Invention
|
Cyclic g-2allylproline in treatment of parkinson's disease. Embodiments of this invention provide... |
|
|
Invention
|
Treatment of non-convulsive seizures in brain injury using g-2-methyl-prolyl glutamate. Aspects o... |
|
2005
|
Invention
|
Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration. This invention provides analogs... |
|
2004
|
Invention
|
Neuroprotective bicyclic compounds and methods for their use. Embodiments of this invention provi... |
|
|
Invention
|
Neuroprotective macrocyclic compounds and methods for their use. Embodiments of this invention pr... |
|
2002
|
Invention
|
Gpe analogs and peptidominetics. This invention relates to analogs and peptidomimetics of glycyl-... |
